Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity

Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity

Abstract The objective of this study is to further analyze recombinant rabies virus-vectored SARS-CoV-2 vaccine, CORAVAX, as an effective COVID-19 vaccine strategy. CORAVAX has proven immunogenic and protective against SARS-CoV-2 in animal models. Here, we have screened adjuvants for the highest qua...

Full description

Bibliographic Details
Main Authors: Catherine Yankowski, Christoph Wirblich, Drishya Kurup, Matthias J. Schnell
Format: Article
Language:English
Published: Nature Portfolio 2022-09-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-022-00532-7

Similar Items

Similar Items